Why the study?
Does subcutaneous low molecular weight heparin improve phlebographic scores and prevent rethrombosis compared to unfractionated heparin in patients with deep vein thrombosis?
Population
149 consecutive patients with phlebographically proven proximal and/or distal deep vein thrombosis of the leg
Comparison
Subcutaneous low molecular weight heparin CY 216… vs Subcutaneous unfractionated heparin in doses…
Design
RCT, randomly allocated, phlebograms were assessed blindly
Follow-up
3 months
Authors
Loading...
LMWH is noninferior to UFH for acute DVT phlebographic improvement; confirms equivalence and supports fixed-dose regimens.
Does subcutaneous low molecular weight heparin improve phlebographic scores and prevent rethrombosis compared to unfractionated heparin in patients with deep vein thrombosis?
Subcutaneous fixed-dose low molecular weight heparin is safe and at least as effective as subcutaneous adjusted-dose unfractionated heparin in the treatment of deep vein thrombosis.
Łopaciuk et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: